Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: Spontaneously mutant selection

Cell Growth and Differentiation

Volumn 10, Issue 7, 1999, Pages 473-478

  Righetti, Sabina C ^a   Perego, Paola ^a   Corna, Elisabetta ^a   Pierotti, Marco A ^a   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PROTEIN P53;

ARTICLE; CELL MUTANT; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; DOSE RESPONSE; DRUG EXPOSURE; GENE AMPLIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC SELECTION; GENOTOXICITY; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL;

ALLELES; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, P53; HUMANS; MUTATION, MISSENSE; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 0032803707     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Weiss, R. B., and Christian, M. C. New cisplatin analogues in development. A review. Drugs, 46: 360-377, 1993.
2. Thigpen, T., Vance, R., Puneky, L, and Khansur, T. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Gynecol. Oncol., 55: 97-107, 1994.
3. Kelland, L. R. The molecular basis of cisplatin sensitivity/resistance. Eur. J. Cancer, 30A: 725-727, 1994.
4. Chu, G. Cellular responses to cisplatin. J. Biol. Chem., 269: 787-790, 1994.
5. Dancey, J., and Le Chevalier, T. Non-small cell lung cancer: an overview of current management. Eur. J. Cancer, 33: S2-S7, 1997.
6. Zunino, F., Perego, P., Pilotti, S., Pratesi, G., Supino, R., and Arcamone, F. Role of apoptotic response in cellular resistance to cytotoxic agents. Pharmacol. Ther., 76: 177-185, 1997.
7. Hickman, J. A. Apoptosis and chemotherapy resistance. Eur. J. Cancer, 32A: 921-926, 1996.
8. Mowat, M. R. A. p53 in tumor progression: life, death and everything. Adv. Cancer Res., 74: 25-48, 1998.
9. Steele, R. J., Thompson, A. M., Hall, P. A., and Lane, D. P. The p53 tumor suppressor gene. Br. J. Surg., 85:1460-1467, 1998.
10. Hartmann, A., Blaszyk, H., Kovach, J. S., and Sommer, S. S. The molecular epidemiology of p53 gene mutations in human breast cancer. Trends Genet., 73; 27-33, 1997.
11. Eliopoulos, A. G., Kerr, D. J., Herod, J., Hodgking, L., Krajewski, S., Reed, J. C., and Young, L. S. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene, 11:1217-1228, 1995.
12. Milner, J. DNA damage, p53 and anticancer therapies. Nat. Med., 7: 879-880, 1995.
13. Fan, S., EI-Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bathia, K., Fornace, A. J., Magrath, I., Kohn, K. W., and O'Connor, M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA-damaging agents. Cancer Res., 54: 5824-5830, 1994.
14. Parego, P., Giarola, M., Righetti, S. C., Supino, R., Caserini, C., Delia, D., Pierotti, M. A., Miyashita, T., Reed, J. C., and Zunino F. Association between cisplatin resistance and mutation of p53 gene and reduced Bax expression in ovarian carcinoma cell systems. Cancer Res., 56:556-562, 1996.
15. Gallagher, W. M., Cairney, M., Schott, B., Roninson, I. B., and Brown, R. Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Oncogene, 14: 185-193, 1997.
16. Righetti, S. C., Della Torre, G., Pilotti, S., Mènard, S., Ottone, F., Colnaghi, M. I., Pierotti, M. A., Lavarino, C., Comarotti, M., Oriana, S., Bötim, S., Bresciani, G. L., Spatti, G., and Zunino, F. A comparative study of p53 gene mutations, protein accumulation and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res., 55: 689-693, 1996.
17. Perego, P., Righetti, S. C., Supino, R., Delia, D., Caserini, C., Carenini, N., Bedogne, B., Broome, E, Krajewski, S., Reed, J. C., and Zunino, F. Role of apoptosis and apoptosis-related proteins in the cisplatin-resistant phenotype of human tumor cell lines. Apoptosis, 2: 540-548,1997.
18. Harris, C. C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst., 88: 1442-1455, 1996.
19. Kirsch, D. G., and Kastan, M. B. Tumor suppressor p53: implications for tumor development and prognosis. J. Clin. Oncol., 76: 3158-3168, 1998.
20. Goldie, J. H., and Coldman, A. J. A mathematic model for relating the drug sensitivity of tumours to their spontaneous mutation rate. Cancer Treat. Rep., 63: 1727-1733, 1979.
21. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A, Weinstein, J. N., Friend, S., Fornace, A. J., Jr., and Kohn K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlation with the growth-inhibitory potency of 123 anticancer agents. Cancer Res., 57: 4285-4300, 1997.
22. Harris, C. C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst., 88: 1442-1455, 1996.
23. Perego, P., Romanelli, S., Carenini, N., Magnani, I, Leone, R., Bonetti, A., Paolicchi, A, and Zunino, F. Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to taxol. Ann. Oncol., 9: 423-430, 1998.
24. Alley, M. C., Scudiero, D. A., Monks, A., Hursey, M. L, Czerwinski, M. J., Fine, D. L., Abbott, B. J., Mayo, J. G., Shoemaker, R. H., and Boyd, M. R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res., 48: 589-601, 1988.
25. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
26. Donghi, R., Longoni, A., Pilotti, S., Michieli, P., Delia Porta, G., and Pierotti, M. A. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J. Clin. Invest, 91: 1753-1760, 1993.
27. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V., and Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (Washington DC), 249: 912-915, 1990.